Nebivolol Ameliorates Cisplatin-Induced Nephrotoxicity in Rats

被引:35
作者
Morsy, Mohamed A. [1 ,2 ]
Heeba, Gehan H. [3 ]
机构
[1] King Faisal Univ, Dept Pharmaceut Sci, Coll Clin Pharm, Al Hasa 31982, Saudi Arabia
[2] Menia Univ, Dept Pharmacol, Fac Med, El Minia, Egypt
[3] Menia Univ, Dept Pharmacol & Toxicol, Fac Pharm, El Minia, Egypt
关键词
ACUTE-RENAL-FAILURE; CONTRAST-INDUCED NEPHROPATHY; CORONARY SMOOTH-MUSCLE; NITRIC-OXIDE; OXIDATIVE STRESS; ANGIOTENSIN-II; CEREBRAL ISCHEMIA/REPERFUSION; RECEPTOR BLOCKADE; HYPERTENSIVE-RATS; INJURY;
D O I
10.1111/bcpt.12538
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Treatment with cisplatin is associated with dose-limiting side effects, mainly nephrotoxicity. On the other hand, nebivolol, a beta(1)-adrenoceptor antagonist, exhibits vasodilatory and antioxidative properties. This study aimed to determine whether nebivolol possesses a protective effect against cisplatin nephrotoxicity and explore many mechanisms underlying this potential effect. Nephrotoxicity was induced in Wistar rats by a single intraperitoneal injection of cisplatin (6 mg/kg) on day 2. Nebivolol (10 mg/kg) was administered orally for 7 consecutive days. Nebivolol showed a nephroprotective effect as demonstrated by the significant reduction in the elevated levels of serum creatinine and urea as well as renal levels of malondialdehyde, nitric oxide products (nitrite/nitrate), inducible nitric oxide synthase, tumour necrosis factor-alpha, caspase-3, angiotensin II and endothelin-1 with a concurrent increase in renal levels of reduced glutathione and endothelial nitric oxide synthase compared to untreated rats. Histopathological examination confirmed the nephroprotective effect of nebivolol. Pre-treatment with N-omega-nitro-L-arginine methyl ester, the non-specific nitric oxide synthase inhibitor, partially altered the protection afforded by nebivolol. In conclusion, nebivolol protects rats against cisplatin-induced nephrotoxicity that is most likely through its antioxidant, anti-inflammatory and antiapoptotic effects as well as by abrogation of the augmented angiotensin II and endothelin-1 levels.
引用
收藏
页码:449 / 455
页数:7
相关论文
共 45 条
  • [1] The usefulness of carvedilol and nebivolol in preventing contrast nephropathy in rats
    Akgullu, Cagdas
    Hekim, Tolga
    Eryilmaz, Ufuk
    Boyacioglu, Murat
    Gungor, Hasan
    Meteoglu, Ibrahim
    Karul, Aslihan
    Onbasili, Osman Alper
    [J]. RENAL FAILURE, 2015, 37 (03) : 511 - 517
  • [2] Nebivolol to attenuate the effects of hyper-homocysteinaemia in rats
    Akgullu, Cagdas
    Huyut, Mustafa Ahmet
    Boyacioglu, Murat
    Gules, Ozay
    Eryilmaz, Ufuk
    Hekim, Tolga
    Dogan, Emir
    Zencir, Cemil
    Gungor, Hasan
    [J]. ATHEROSCLEROSIS, 2015, 240 (01) : 33 - 39
  • [3] Renoprotective Effects of Gamma-Aminobutyric Acid on Cisplatin-induced Acute Renal Injury in Rats
    Ali, Badreldin H.
    Al-Salam, Suhail
    Al Za'abi, Mohammed
    Al Balushi, Khalid A.
    AlMahruqi, Ahmed S.
    Beegam, Somyia
    Al-Lawatia, Intisar
    Waly, Mostafa I.
    Nemmar, Abderrahim
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 116 (01) : 62 - 68
  • [4] Thalidomide Ameliorates Cisplatin-Induced Nephrotoxicity by Inhibiting Renal Inflammation in an Experimental Model
    Amirshahrokhi, Keyvan
    Khalili, Ali-Reza
    [J]. INFLAMMATION, 2015, 38 (02) : 476 - 484
  • [5] [Anonymous], ISRN TOXICOL
  • [6] Bakris GL, 2007, J MANAGE CARE PHARM, V13, pS9
  • [7] Brehm BR, 2000, J CARDIOVASC PHARM, V36, pS401, DOI 10.1097/00005344-200036001-00117
  • [8] Buege J A, 1978, Methods Enzymol, V52, P302
  • [9] Selective iNOS inhibition reduces renal damage induced by cisplatin
    Chirino, Yolanda I.
    Trujillo, Joyce
    Javier Sanchez-Gonzalez, Dolores
    Maria Martinez-Martinez, Claudia
    Cruz, Cristino
    Bobadilla, Norma A.
    Pedraza-Chaverri, Jose
    [J]. TOXICOLOGY LETTERS, 2008, 176 (01) : 48 - 57
  • [10] Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity
    Chirino, Yolanda I.
    Pedraza-Chaverri, Jose
    [J]. EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 2009, 61 (03) : 223 - 242